<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680641</url>
  </required_header>
  <id_info>
    <org_study_id>2007RESP06</org_study_id>
    <nct_id>NCT00680641</nct_id>
  </id_info>
  <brief_title>Simvastatin in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of East Anglia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of East Anglia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effects of 2 months therapy with simvastatin 40mg once per day compared to&#xD;
      placebo in a double-blind placebo-controlled study of patients with COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statins (HMG-Coenzyme A reductase inhibitors) are widely used clinically as lipid lowering&#xD;
      drugs; however they have also been shown to exhibit anti-inflammatory and anti-oxidant&#xD;
      properties(1). Recently published large retrospective cohort studies, in patients with&#xD;
      chronic obstructive pulmonary disease (COPD), suggest that statins reduce mortality and COPD&#xD;
      related admissions(2). Possible mechanisms of action include effects on cell adhesion&#xD;
      molecules, changes in inflammatory mediator release, antioxidant effect and increased&#xD;
      clearance of apoptoic cells. Simvastatin has been shown to reduce the development of smoking&#xD;
      induced emphysema in rats with reductions in MMP-9 activity and simvastatin withdrawal leads&#xD;
      to increased MMP levels in hypercholesterolaemic patients. Serum concentrations of TNFa and&#xD;
      high sensitive C Reactive protein(3) (hs-CRP) are reduced with simvastatin therapy in&#xD;
      patients with hypercholesterolaemia and risk of cardiovascular disease respectively. No&#xD;
      clinical trial has directly evaluated the clinical effects of statins in patients with COPD&#xD;
      in terms of induced sputum MMP profile, alveolar nitric oxide or pulmonary physiology.&#xD;
&#xD;
      We have modified our published method of RNA purification, developed to purify RNA from&#xD;
      cartilage, tendon or synovium(4), to yield good quality RNA from sputum with relative&#xD;
      simplicity and low cost. We have identified MMP-2, -9 and -14 in the sputum of healthy&#xD;
      volunteers (unpublished pilot data) and will utilise this technique in the current study.&#xD;
      Exhaled breath condensate (EBC) is completely non-invasive, requires no co-operation from&#xD;
      individuals and provides information about a number of inflammatory and oxidation pathways.&#xD;
      Markers of oxidative stress (8-isoprostane and hydrogen peroxide) and nitric oxide products&#xD;
      can be measured in exhale breath condensate(5) and are related to disease activity in&#xD;
      patients with COPD. Markers of oxidative stress increase in concentration in EBC during&#xD;
      exacerbations of COPD are reduced after treatment with the antioxidant N-acetyl cysteine(6).&#xD;
      Hydrogen peroxide is not stable and therefore 8-isoprostane is a preferable marker of&#xD;
      oxidative stress unless the sample is measured on line.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in serum high sensitivity C-reactive protein (HsCRP) between simvastatin and placebo</measure>
    <time_frame>4 checks over a four month period at 2 weeks, 10 weeks, 14 weeks and 22 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference between treatment with simvastatin and placebo for Clinical COPD Questionnaire</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between treatment with simvastatin and placebo for Spirometry - FEV1, FVC, FEV1/FVC ratio</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between treatment with simvastatin and placebo for Induced sputum differential cell count</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between treatment with simvastatin and placebo for Induced sputum mRNA for MMP and TIMPs</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between treatment with simvastatin and placebo for Exhaled breath condensate 8-isoprostane concentration</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between treatment with simvastatin and placebo for Serum TNFa</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between treatment with simvastatin and placebo for Cholesterol</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COPD</condition>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40mg of Simvastatin once daily</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>40mg of placebo once daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged more than 45 years.&#xD;
&#xD;
          -  Physician labelled diagnosis of chronic obstructive pulmonary disease,emphysema or&#xD;
             chronic bronchitis.&#xD;
&#xD;
          -  Smoker or ex-smoker with a pack year smoking history of greater than 20 pack years&#xD;
&#xD;
          -  FEV1 30-70% predicted&#xD;
&#xD;
          -  FEV1/FVC&lt; 70%&#xD;
&#xD;
          -  Body Mass Index &lt;25kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Cardiac or pulmonary disease other than chronic obstructive pulmonary disease.&#xD;
&#xD;
          -  Untreated hypothyroidism&#xD;
&#xD;
          -  Respiratory infection defined as fever, nasal/sinus congestion, fatigue, cough,&#xD;
             antibiotic use or yellow/green sputum within 4 weeks prior to study.&#xD;
&#xD;
          -  Receiving current oral corticosteroid therapy or leukotriene modifying therapy.&#xD;
&#xD;
          -  Severe or uncontrolled co-morbid disease&#xD;
&#xD;
          -  History of atopy or asthma&#xD;
&#xD;
          -  Clinical history of bronchiectasis&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Women of child-bearing potential, unless adequate contraception is used (ie&#xD;
             contraceptive pill or double-barrier contraception - partner using condom and subject&#xD;
             using spermicide, diaphragm, intra-uterine device or contraceptive sponge)&#xD;
&#xD;
          -  Unable to give written informed consent&#xD;
&#xD;
          -  Patients receiving a statin prior to entry into the study&#xD;
&#xD;
          -  Hypersensitivity to simvastatin or to any of the excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew M Wilson, MD, MRCP (UK)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Senior Lecturer, University of East Anglia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRTU University of East Anglia</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR47TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRTU Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR74UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006 Aug;61(8):729-34. Review.</citation>
    <PMID>16877692</PMID>
  </reference>
  <reference>
    <citation>Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007 Feb;29(2):279-83. Epub 2006 Oct 18.</citation>
    <PMID>17050558</PMID>
  </reference>
  <reference>
    <citation>Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007 Jan 23;49(3):290-7. Epub 2007 Jan 8.</citation>
    <PMID>17239709</PMID>
  </reference>
  <reference>
    <citation>Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, Brockbank SM, Edwards DR, Parker AE, Clark IM. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 2004 Jan;50(1):131-41.</citation>
    <PMID>14730609</PMID>
  </reference>
  <reference>
    <citation>Montuschi P. Exhaled breath condensate analysis in patients with COPD. Clin Chim Acta. 2005 Jun;356(1-2):22-34. Epub 2005 Mar 23. Review.</citation>
    <PMID>15936301</PMID>
  </reference>
  <reference>
    <citation>Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med. 2001 Jun;95(6):448-56.</citation>
    <PMID>11421501</PMID>
  </reference>
  <reference>
    <citation>van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003 Apr 28;1:13.</citation>
    <PMID>12773199</PMID>
  </reference>
  <reference>
    <citation>Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):308-17.</citation>
    <PMID>8756799</PMID>
  </reference>
  <reference>
    <citation>Standardization of spirometry--1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis. 1987 Nov;136(5):1285-98.</citation>
    <PMID>3674589</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Andrew M Wilson</name_title>
    <organization>University of East Anglia</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

